DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom’s global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo’s commercial teams where he oversaw the consolidation of its worldwide hospital sales, OEM, alternate care sales, and clinical teams along with the customer service and hospital conversion teams.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Positive Outlook for Dexcom: Buy Rating Backed by Promising CGM Technology and Market Growth Potential
- Insulet expands Omnipod 5 to four more International markets
- Optimistic Buy Rating for Dexcom Despite FDA Warning Letter
- Dexcom Expands Board with New Director Appointment
- Dexcom’s Resilience Amid FDA Warning: Buy Rating Justified by Strong Long-Term Prospects